secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001558370-22-017582
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Q3 net loss widens to $13.6M; trial enrollment delays, cash runway to 2H25
--------------------------------------------------------------------------------

- Net loss $13.6M for Q3 2022 vs $6.2M in Q3 2021; R&D expenses tripled to $10.8M.
- Cash and investments $142.6M as of Sep 30, 2022, down from $167.4M at Dec 31, 2021; runway into 2H25.
- IMPAHCT Phase 2b/3 trial enrollment delayed; topline data expected Q4 2023 or Q1 2024.
- Expanded IP with two new U.S. patents (11,413,289 and 11,464,776) issued; notice of allowance for another.
- Sanjeev Khindri joined as SVP Clinical Development; brings respiratory and PAH experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/0001558370-22-017582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/tmb-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer